The global pancreatic cancer treatment market size is expected to reach USD 6.98 billion by 2030, registering a CAGR of 13.9% during the forecast period, according to a new report by Grand View Research, Inc. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period.
According to an article published in the National Center for Biotechnology Information in 2015, pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Furthermore, pancreatic cancer is expected to be the second common cause of death in the U.S., by 2030. These factors together would propel the market growth in the forecast period.
Request a free sample copy or view report summary: Pancreatic Cancer Treatment Market Report
The study suggests that exocrine cancer is by far the most common type of pancreatic cancer accounting for more than 95% of the overall pancreatic cancer types.
Among the treatment types, targeted therapy occupied the largest share since it is considered as the most effective treatment option, which blocks the growth and spread of cancer cells without damaging healthy cells.
North America dominated the segment with the largest revenue share in 2023 due to high adoption rate of advanced treatment options and highly developed healthcare infrastructure.
Asia Pacific is anticipated to show a significant growth during the forecast period, mainly due to increasing government initiatives, growing awareness regarding the treatment options for pancreatic cancer, and the availability of highly sophisticated medical infrastructure for effective treatment.
Grand View Research has segmented the global pancreatic cancer treatment market based on type, treatment, end-use, and region:
Pancreatic Cancer Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)
Exocrine
Endocrine
Pancreatic Cancer Treatment Treatment Outlook (Revenue, USD Million, 2018 - 2030)
Chemotherapy
Radiation Therapy
Others
Pancreatic Cancer Treatment End-use Outlook (Revenue, USD Million, 2018 - 2030)
Hospital Pharmacies
Retail Pharmacies
Others
Pancreatic Cancer Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Mexico
Canada
Europe
Germany
UK
France
Italy
Spain
Denmark
Norway
Sweden
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
Middle East and Africa (MEA)
Saudi Arabia
UAE
Kuwait
South Africa
List of Key Players in the Pancreatic Cancer Treatment Market
AstraZeneca
Novartis AG
Pfizer Inc
Genentech, Inc
Bristol-Myers Squibb Company
Ipsen Pharma Oncolytics Biotech Inc
TME Pharma
Phaxiam
"The quality of research they have done for us has been excellent..."